何鹏兴
郑州大学药学院副教授，硕士生导师
邮箱：hepengxing@zzu.edu.cn
个人简介
何鹏兴，副教授，硕士生导师。博士毕业于浙江大学药学院，获医学博士学位；2011-2014年在中科院上海药物所丁健院士课题组进行肿瘤药理学研究；2014年7月起至今在郑州大学工作；2022年12月-2023年12月以访问学者身份在美国加州大学欧文分校进行科研工作。主持有国家自然科学基金-河南联合基金、河南省自然科学基金、中国博士后科学基金等多个项目。目前已在Cell Death & Disease，Acta Pharmaceutica Sinica B，Genes & Diseases，Biomedicine & Pharmacotherapy，Theranostics，Oncotarget，Acta Pharmacologica Sinica，Life Sciences，European Journal of Pharmacology等国际学术刊物发表SCI论文16篇。
教学与教研
本科生课程《药理学》
研究生课程《高等药理》
科研项目
（1）国家自然科学基金河南联合基金，U2004101，ATRA上调胃癌细胞PD-L1的分子机制及与PD-L1抗体药物联用的抗肿瘤作用研究，2021-01至2023-12，50万元，主持；
（2）河南省自然科学基金，162300410303，TGF-β1调控胃癌细胞表面免疫抑制分子PD-L1表达的机制及其功能研究，2017-01至2019-12，10万元，主持；
（3）中国博士后科学基金面上项目，2015M572123，抑制LSD1导致胃癌细胞周期阻滞并增敏DNA毒剂的机制，2015-01至2016-09，5万元，主持；
研究与成果
代表性文章：
(1) Yajie Liu*; Pengxing He*; Xubin Ma; Yingqi Tian; Yu Zhang; Yang Wang; Yingjie Jia; Hongmin Liu; Ying Liu; Yichao Xu; The combination of SLC7A11 inhibitor and oridonin synergistically inhibits cervical cancer cell growth by decreasing the NADPH/NADP+ ratio, Genes & Diseases, 2024, online, 101265.
(2) Huiyun Wei; Yingying Zhang; Yilin Jia; Xunan Chen; Tengda Niu; Aniruddha Chatterjee; Pengxing He#; Guiqin Hou#; Heat shock protein 90: biological functions, diseases, and therapeutic targets, MedComm, 2024, 5(2): e470.
(3) Linna Du; Han Yang; Yufei Ren; Yanli Ding; Yichao Xu; Xiaolin Zi; Hongmin Liu; Pengxing He#; Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced antitumor effects with ferroptosis inducers in NSCLC, Cell Death Disease, 2023, 14(11): 716.
(4) Pengxing He; Jing Jing; Linna Du; Xuyang Zhang; Yufei Ren; Han Yang; Bin Yu; Hongmin Liu; Discovery of YS-363 as a highly potent, selective, and orally e ffi cacious EGFR inhibitor, Biomedicine Pharmacotherapy, 2023, 167: 115491.
(5) Pengxing He; Linna Du; Qingqing Dai; Guobo Li; Bin Yu; Linlin Chang; Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors, Bioorganic Chemistry, 2023, 142:106970.
(6) Xuyang Zhang; Pan Hao; Junwei Wang; Wen Zhao#; Hongmin Liu#; Pengxing He#; Inhibition of lysine-specific demethylase 1 enhances the sensitivity of the chemotherapeutic drug doxorubicin in gastric cancer cell. Molecular Biology Reports, 2023, 50: 507-516.
(7) Pengxing He; Linna Du; Pan Hao; HanYang; Yufei Ren; Huiqin Kang; Yanli Ding; Wen Zhao; Yichao Xu; Hongmin Liu; Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma, Genes & Diseases, 2022, 10(5): 1779-1782.
(8) Zhi-lu Ma; Yan-li Ding; Jing Jing; Lin-na Du; Xu-yang Zhang; Hong-min Liu#; Peng-xing He#; ATRA promotes PD-L1 expression to control gastric cancer immune surveillance. European Journal of Pharmacology, 2022, (920): 174822.
(9) Zhiru Wang; Wenting Kang; Ouwen Li; Fengyu Qi; Junwei Wang; Yinghua You; Pengxing He; Zhenhe Suo; Yichao Zheng; Hong-Min Liu; Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica B, 2021, 11(3): 694-707.
(10) Pengxing He; Zhilu Ma; Huan Han; Xuyang Zhang; Shenghui Niu; Linna Du; Yichao Zheng; Hongmin Liu; Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer. Life Sciences, 2020, 242: 117247.
(11) Pengxing He; Shenghui Niu; Shuai Wang; Xiaojing Shi; Siqi Feng; Linna Du; Xuyang Zhang; Zhilu Ma; Bin Yu; Hongmin Liu; Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor, Acta Pharmaceutica Sinica B, 2019, 9(6): 1193-1203.
(12) Jie Zhang; Yafang Wang; Yanyan Shen; Pengxing He; Jian Ding; Yi Chen; G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. Theranostics, 2018, 8(10): 2884-2895.
(13) Zheng YC, Yu B, Jiang GZ, Feng XJ, He PX, Chu XY, Zhao W, Liu HM. Irreversible LSD1 inhibitors: Application of tranylcypromine and its derivatives in cancer treatment. Current Topics in Medicinal Chemistry, 2016, 16(19): 2179-2188.
(14) Jie Zhang; Pengxing He; Yong Xi; Meiyu Geng; Yi Chen; Jian Ding; Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Oncotarget, 2015, 6(5): 2917-2927.
(15) Pengxing He; Jie Zhang; Yongsheng Che; Qiaojun He; Yi Chen; Jian Ding; G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation. Acta Pharmacologica Sinica, 2014. 35(12): 1546-1555.
(16) Pengxing He; Jie Zhang; Yongsheng Che; Qiaojun He; Yi Chen; Jian Ding; G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspase-dependent apoptosis in human breast cancer cells in vitro. Acta Pharmacologica Sinica, 2014. 35(8): 1055-1064.
